{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-088950","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.774734+00:00","generated_at":"2026-05-31T13:43:13.920668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Precision BioSciences Q2 2024 net income $32.7M; cash $123.6M; HBV program on track for IND in 2024","bullets":["Net income from continuing ops $32.7M vs loss $11.9M YoY; revenue $49.9M (+$30.1M) from Prevail termination.","Cash $123.6M; expected runway into H2 2026.","PBGENE-HBV on track for IND/CTA submission in 2024; PBGENE-PMM targeted for 2025.","Regained control of three preclinical programs from Prevail (DMD, liver, CNS) for internal/partner development.","Entered into $22.5M term loan with Banc of California (maturity June 2027)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-088950","json":"https://secwatch.observer/filing/0000950170-24-088950.json","markdown":"https://secwatch.observer/filing/0000950170-24-088950.md","text":"https://secwatch.observer/filing/0000950170-24-088950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024088950/0000950170-24-088950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024088950/dtil-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:43:13.920668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}